Ivana Magovcevic-Liebisch, PhD, JD
Dr. Magovcevic-Liebisch has served as a member of our board of directors since August 2020 and its chairperson since January 2021. Dr. Magovcevic-Liebisch has served as the President and Chief Executive Officer and as a member of the board of directors of Vigil Neuroscience, Inc. (NASDAQ: VIGL) since July 2020. Prior to Vigil, Dr. Magovcevic-Liebisch was Executive Vice President, Chief Business Officer at Ipsen, a pharmaceutical company, from March 2018 to April 2020, where she led the External Innovation, Business Development and Alliance Management functions. Prior to Ipsen, Dr. Magovcevic-Liebisch was Executive Vice President, Chief Strategy and Corporate Development Officer at Axcella Health Inc. (NASDAQ: AXLA) from May 2017 to March 2018, and Senior Vice President, Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) from March 2013 to May 2017. Dr. Magovcevic-Liebisch previously worked at Dyax Corp. (acquired by Shire plc (NASDAQ: SHPG)) from April 2001 to March 2013 in management roles of increasing scope and responsibility, including Executive Vice President and Chief Operating Officer, where she launched the company’s first drug, Kalbitor® for an orphan indication, Hereditary Angiodema. Dr. Magovcevic-Liebisch began her biopharmaceutical career at Transkaryotic Therapies, Inc., where she was Director of Intellectual Property and Patent Counsel from 1998 to 2001. Dr. Magovcevic-Liebisch is currently a member of the board of directors of Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) and previously served as a member of the board of directors of Applied Genetic Technologies Corporation (NASDAQ: AGTC). She is also a trustee of the Boston Museum of Science and of the Boston Ballet, and overseer of Beth Israel Deaconess Medical Center. She received a B.A. in Biology and Chemistry from Wheaton College, a Ph.D. in Genetics from Harvard University, and a J.D. in High Technology Law from Suffolk University Law School.